Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Study of Omidubicel for Hematological Malignancies
NCT04260698Phase 3Completed
- Sponsor
- Gamida Cell
- Start
- Jul 2020
- Primary completion
- May 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of omidubicel in hematological malignancies, sponsored by Gamida Cell. Started Jul 2020; status: completed.
02
Drugs
omidubicel
03
Conditions
hematological malignancies
Beyond the preview
Go deeper on NCT04260698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260698.